A gene-editing therapy can be approved and treating patients before the patents most specific to it even issue. US12497614B2 - Vertex's 2025 beta-globin editing grant - and US12385070B2, Seattle Children's 2025 "Homology directed repair compositions for the treatment of hemoglobinopathies," both issued in 2025 around an editing approach that had already reached the clinic.
The mechanics matter. A U.S. patent's term runs twenty years from the earliest non-provisional priority date, not from issue, so a 2025 grant in a chain reaching back years has a horizon set by that earlier date. But continuation practice lets an applicant keep filing fresh claims off the same specification, each issuing later and each covering the product from a new angle - layering protection around a marketed therapy.
That is why a single expiry date never describes a gene-therapy franchise's exclusivity. The protection is the envelope of foundational architecture claims, target-and-edit product claims, cell-process claims, and method claims - issuing across years, sharing priority dates but reaching the product differently. Reading exclusivity off the newest grant's issue date overstates it; reading it off the oldest understates the breadth.
The editorial discipline here is to separate term from coverage. Term is fixed by the priority chain and adjusted by any patent-term adjustment for USPTO delay. Coverage is what the family of claims, old and new, actually reaches. A late-2025 grant does not extend the term of an early-priority family, but it can add coverage that closes a gap a competitor hoped to exploit.
For anyone modeling when a competing hemoglobinopathy editing therapy could enter, the lesson is to map the whole family - priority dates, continuations, the upstream architecture licenses, and any term adjustments - rather than anchoring on one number. The 2025 Vertex and Seattle Children's grants are a reminder that the exclusivity picture keeps filling in for years after a gene therapy launches.